At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 7 enrolled
Drug / intervention
Pembrolizumab +1 moredrug
Likely dose
Pembrolizumab 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab and Tadalafil for Head and Neck Cancer and 11 related conditions. Completed, enrolled 7 participants across 1 site.
Detailed Summary
This study will examine the combination of pembrolizumab and tadalafil for safety and efficacy in advanced head and neck cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHead and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Carcinoma, Head and Neck Cancer Stage III, Head and Neck Cancer Stage IV, Head and Neck Cancer Metastatic, Cancer, Cancer of Esophagus, Cancer, Metastatic, Cancer of Head and Neck, Cancer of Mouth, Cancer of Neck
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedJun 2019
Enrollment StartApr 2020
Primary CompletionApr 2022
Study CompletionJan 2024
TodayJul 2026
First PostedJun 20, 2019
Enrollment StartApr 7, 2020
Primary CompletionApr 16, 2022
Study CompletionJan 9, 2024
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 7.0 years ago
Interventions
Pembrolizumabdrug
200 mg intravenously every 3 weeks
Tadalafildrug
10 mg by mouth daily